140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLCEnriqueta Felip, Apar Kishor Ganti, Óscar Juan et al.|Annals of Oncology|2021Cited by 1